Bolt Biotherapeutics, Inc. (BOLT): who owns it and who trades it
As of Nov 16, 2026, BOLT insiders reported 9 open-market sales worth $128K and 4 purchases worth $324K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was William P. Quinn (CEO), with $58.4K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Bolt Biotherapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, BOLT insiders reported $324K of open-market purchases and $128K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Coastlands Capital LP | 10% owner | Purchase | 50,000 | $6.38 | $319K | Form 4 |
| Sep 18, 2026 | Grant Yonehiro | Chief Operating Officer | Sale | 6,850 | $3.24 | $22.2K | Form 4 |
| Sep 18, 2026 | Sarah Nemec | Vice president | Sale | 4,077 | $3.24 | $13.2K | Form 4 |
| Sep 18, 2026 | William P. Quinn | CEO | Sale | 9,132 | $3.24 | $29.6K | Form 4 |
| Sep 17, 2026 | Grant Yonehiro | Chief Operating Officer | Sale | 4,909 | $3.32 | $16.3K | Form 4 |
| Sep 17, 2026 | Sarah Nemec | Vice president | Sale | 2,922 | $3.32 | $9.7K | Form 4 |
| Sep 17, 2026 | William P. Quinn | CEO | Sale | 6,545 | $3.32 | $21.7K | Form 4 |
| Sep 16, 2026 | Grant Yonehiro | Chief Operating Officer | Sale | 1,417 | $3.77 | $5.3K | Form 4 |
| Sep 16, 2026 | Sarah Nemec | Vice president | Sale | 843 | $3.77 | $3.2K | Form 4 |
| Sep 16, 2026 | William P. Quinn | CEO | Sale | 1,889 | $3.77 | $7.1K | Form 4 |
| Jun 5, 2026 | Sarah Nemec | Vice president | Purchase | 509 | $3.88 | $2K | Form 4 |
| Jun 5, 2026 | William P. Quinn | CEO | Purchase | 637 | $3.88 | $2.5K | Form 4 |
| Dec 5, 2025 | William P. Quinn | CEO | Purchase | 125 | $4.61 | $576 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Coastlands Capital LP | 10% owner | $319K | – | Nov 9, 2026 |
| William P. Quinn | President, CEO and CFO, Director | $3K | $58.4K | Sep 18, 2026 |
| Grant Yonehiro | Chief Operating Officer | – | $43.8K | Sep 18, 2026 |
| Sarah Nemec | Senior VP, Finance and PAO | $2K | $26.1K | Sep 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BOLT short interest
Low short interest. 2.5% of BOLT shares are sold short: about 1 share in 41. Over the last 12 reports the number of shares short went up 291%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 47,382 BOLT shares were sold short, 2.5% of the shares outstanding, up 200.8% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 47,382 | 2.46% | +201% | 1.26M | 1.0 |
| Oct 15, 2026 | 15,751 | 0.82% | -39% | 26,150 | 1.0 |
| Sep 30, 2026 | 25,736 | 1.34% | +39% | 42,277 | 1.0 |
| Sep 15, 2026 | 18,486 | 0.96% | +19% | 30,445 | 1.0 |
| Aug 31, 2026 | 15,579 | 0.81% | +1923% | 17,581 | 1.0 |
| Aug 14, 2026 | 770 | 0.04% | -79% | 34,611 | 1.0 |
| Jul 31, 2026 | 3,749 | 0.20% | -35% | 12,715 | 1.0 |
| Jul 15, 2026 | 5,761 | 0.30% | -65% | 17,142 | 1.0 |
| Jun 30, 2026 | 16,698 | 0.87% | -39% | 39,560 | 1.0 |
| Jun 15, 2026 | 27,250 | 1.42% | +108% | 24,781 | 1.1 |
| May 29, 2026 | 13,125 | 0.68% | +8% | 34,638 | 1.0 |
| May 15, 2026 | 12,126 | 0.63% | +73% | 23,966 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Bolt Biotherapeutics company events
Bolt Biotherapeutics filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 23, 2026.
- Oct 23, 2026LeadershipAppointment of Director In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board. Filing
- Oct 6, 2026AgreementBolt Biotherapeutics, Inc. entered into the Second Amendment to Lease with HCP LS Redwood City LLC, as landlord. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Bolt Biotherapeutics financials
Famous investors that hold BOLT
2 of the 50 well-known investors we track reported holding BOLT in their latest 13F filing. The largest position is Jim Simons's, worth $342K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 92,925 | $342K | 0.0% | -6% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 18,300 | $67.3K | 0.0% | -68% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BOLT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Renaissance Technologies LLC | 13G/A | 4.8% |
| Nov 12, 2026 | Renaissance Technologies LLC | 13G/A | 4.8% |
| Nov 6, 2026 | Coastlands Capital LP | 13G | 17.5% |
| Nov 6, 2026 | Coastlands Capital LP | 13G | 17.5% |
Questions about Bolt Biotherapeutics, Inc. (BOLT) stock
Are BOLT insiders buying or selling?
In the last 12 months, BOLT insiders reported 4 open-market purchases worth $324K and 9 sales worth $128K. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in BOLT?
As of Oct 30, 2026, 47,382 BOLT shares were sold short, 2.5% of the shares outstanding, up 200.8% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold BOLT?
2 of the 50 well-known investors we track reported BOLT in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $342K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.